ubs global pharmaceuticals conference may 23 2005 rj kirk chairman and ceo krish krishnan cfo coo forward looking statements this presentation contain that reflect management s current views as to the company clinical trials regulatory approval process product development research programs other future events operations these involve uncertainties risks are detailed in annual report on form 10 k filed with sec april 1 well public filings actual results could differ materially from investment thesis a platform technology yielding proprietary products offer significant advantages low technical risk short pathway facing timely market demand favorable climate pipeline nrp104 carrierwave tm amphetamine phase 3 efficacy study completed an anticipated nda filing date by end of nrp290 hydrocodone anticipate ind q2 nrp369 oxycodone q4 we working active based business overview conditionally bioreversible derivative
